Are Clinically Insignificant Prostate Cancers Really Insignificant Among Korean Men?

Yonsei Medical Journal

Volumn 53, Issue 2, 2012, Pages 358-362

  Yeom, Chan Dong ^a   Lee, Seung Hwan ^a   Park, Kyung Kgi ^b   Park, Sang Un ^a   Chung, Byung Ha ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Clinically insignificant; Gleason score; Prostate; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER INVASION; GLEASON SCORE; HUMAN; INSIGNIFICANT PROSTATE CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; REVIEW; SEMINAL VESICLE;

AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84863125321     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.2.358     Document Type: Review

References (20)

1. Chun FK, Briganti A, Gallina A, Hutterer GC, Shariat SF, Antebie E, et al. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol 2007;52: 1067-74.
2. Yin M, Bastacky S, Chandran U, Becich MJ, Dhir R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol 2008;179:892-5.
3. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of non palpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
4. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004;101:2001-5.
5. Chung JS, Choi HY, Song HR, Byun SS, Seo SI, Song C, et al. Nomogram to predict insignificant prostate cancer at radical prostatectomy in Korean men: a multi-center study. Yonsei Med J 2011;52:74-80.
6. Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, Doo SH, et al. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. BJU Int 2010;105:1526-30.
7. Hekal IA, El-Tabey NA, Nabeeh MA, El-Assmy A, Abd El-Hameed M, Nabeeh A, et al. Validation of Epstein criteria of insignificant prostate cancer in Middle East patients. Int Urol Nephrol 2010;42:667-71.
8. Chun FK, Briganti A, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, et al. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 2007;43:536-43.
9. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001;165:1554-9.
10. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC. Mor-phometric measurement of tumor volume and percent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol 1989;141:341-5.
11. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003;170(2 Pt 1):370-2.
12. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, et al. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:1306-13.
13. Song C, Ro J Y, Lee MS, Hong SJ, Chung BH, Choi H Y, et al. Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology 2006;68:820-4.
14. Man A, Pickles T, Chi KN; British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer. J Urol 2003;170:901-4.
15. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163:824-7.
16. Kim HS, Jeon SS, Choi JD, Kim W, Han DH, Jeong BC, et al. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL. Urology 2010;76:919-22.
17. Sokoloff MH, Yang XJ, Fumo M, Mhoon D, Brendler CB. Characterizing prostatic adenocarcinomas in men with a serum prostate specifc antigen level of < 4.0 ng/mL. BJU Int 2004;93:499-502.
18. Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Toch-ner Z, Wein AJ. Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med 2004;164:1227-30.
19. Chun FK, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T, et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006;49:820-6.
20. Singh J, Trabulsi EJ, Gomella LG. Is there an optimal management for localized prostate cancer? Clin Interv Aging 2010;5:187-97.